Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 6/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21995056 | 1.00 | LRRK2 (0.44) | LRRK2ATMNCF1TNFAPP | |
| SCHEMBL22749310 | 0.89 | LRRK2 (0.46) | LRRK2ATMNCF1APPKDM1A | |
| SCHEMBL22749313 | 0.89 | LRRK2 (0.46) | LRRK2ATMNCF1APPKDM1A | |
| SCHEMBL29508390 | 0.89 | LRRK2 (0.46) | LRRK2ATMNCF1APPKDM1A | |
| SCHEMBL29508381 | 0.86 | LRRK2 (0.44) | LRRK2ATMNCF1TNFAPP | |
| SCHEMBL22749278 | 0.85 | LRRK2 (0.41) | LRRK2NCF1APPTLR7KDM4E | |
| SCHEMBL22749279 | 0.85 | LRRK2 (0.41) | LRRK2NCF1APPTLR7KDM4E | |
| SCHEMBL22749276 | 0.84 | LRRK2 (0.40) | LRRK2ATMTNF | |
| SCHEMBL22749275 | 0.84 | LRRK2 (0.40) | LRRK2ATMTNF | |
| SCHEMBL22749304 | 0.83 | LRRK2 (0.39) | LRRK2ATMNCF1TNFTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540137-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-02-03 | — | — | US | disclosed |
| US-20240300947-A1 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-09-12 | — | — | US | disclosed |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-07-02 | — | — | US | disclosed |
| CN-113166143-B | N-1 branched alkyl ether substituted imidazo [4,5-c ] quinoline compounds, compositions and methods | 舒万诺知识产权公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3887369-B1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20220177471-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-06-09 | — | — | US | disclosed |
| EP-3980415-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M Innovative Properties Company (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-113924297-A | N-1 branched alkyl substituted imidazo [4,5-c ] quinoline compounds, compositions, and methods | 3M创新有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20210323962-A1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2021-10-21 | — | — | US | disclosed |
| EP-3887369-A1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M Innovative Properties Company (US) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020245706-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020109898-A1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540137-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IRF3, IFNAR1, IFNG | LRRK2 1295/4885ATM 680/4885NCF1 1438/4885 |
| US-20240300947-A1 | N-1 Branched Alkyl Ether Substituted Imidazo[4,5-c]Quinoline Compounds, Compositions, and Methods | IFNG, IFNAR1, IRF3 | LRRK2 3506/4885ATM 3994/4885NCF1 81/4885 |
| US-20210323962-A1 | N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, IRF3 | LRRK2 2912/4885ATM 3675/4885NCF1 95/4885 |
| US-20220177471-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, IRF3 | LRRK2 2522/4885ATM 3655/4885NCF1 71/4885 |
| US-12024514-B2 | N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, IRF3 | LRRK2 2912/4885ATM 3675/4885NCF1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.